Cas No.: | 2219362-41-9 |
Chemical Name: | (S)-2-(tert-butoxy)-2-(7-(4-chlorophenyl)-5-methyl-2-(1-methyl-3-(1-(oxetan-3-yl)piperidin-4-yl)-1H-indazol-5-yl)benzo[d]thiazol-6-yl)acetic acid |
Synonyms: | GS-9822,GS 9822,GS9822 |
SMILES: | C(O)(=O)[C@H](OC(C)(C)C)C1=C(C)C=C2C(=C1C1=CC=C(Cl)C=C1)SC(C1C=CC3=C(C=1)C(C1CCN(C4COC4)CC1)=NN3C)=N2 |
Formula: | C36H39ClN4O4S |
M.Wt: | 659.242 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | GS-9822 is a potent, non-catalytic site HIV integrase inhibitor with wild type EC50 of 3 nM.GS-9822 retains potency against mutant viruses resistant to other classes of antiretroviral agents, including protease and strand transfer integrase inhibitors.GS-9822 induces a shift in CCD helix that appears to be a result of trying to accommodate the oxetanyl piperidine moiety with shift induced by T174I mutation.Projected once-daily oral dosing makes GS-9822 suitable for combination with other ARVs.A unique and difficult-to-monitor urothelial toxicity observed in cynomolgus monkeys poses a formidable challenge for further development of GS-9822. |